Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-adrenergic blocking agents: past, present, and future perspectives.

J A Franciosa1

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA. jfranciosa@compuserve.com

Coronary Artery Disease
|September 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.

Journal of cardiac failure·2000
Same author

Commentary on the use of run-in periods in clinical trials.

The American journal of cardiology·1999
Same author

Acute hemodynamic effects of norepinephrine inhibition in patients with severe chronic congestive heart failure.

Journal of the American College of Cardiology·1989
Same author

Beta-receptor-active agents: role of partial agonists in patients with heart failure.

Journal of cardiovascular pharmacology·1989
Same author

Application of noninvasive techniques for measuring cardiac output in hypertensive patients.

American heart journal·1988
Same author

The role of new antihypertensive drugs.

Chest·1988
Same journal

Comparative effectiveness of Orsiro, Xience, Synergy, and Resolute stent in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry study.

Coronary artery disease·2026
Same journal

Close separate origin of the left anterior descending and circumflex coronary arteries with a coexisting aorta-right atrial tunnel.

Coronary artery disease·2026
Same journal

Percutaneous repair following massive perforation of the right coronary artery with stent deployment toward the pericardium.

Coronary artery disease·2026
Same journal

De-escalation from prasugrel to clopidogrel at the 12-month landmark after percutaneous coronary intervention with drug-eluting stents for acute myocardial infarction: a Korea Acute Myocardial Infarction Registry-National Institutes of Health cohort study.

Coronary artery disease·2026
Same journal

Serum magnesium predicts new-onset atrial fibrillation in ST-segment elevation myocardial infarction patients after primary percutaneous coronary intervention.

Coronary artery disease·2026
Same journal

Symptomatic anomalous aortic origin of the right coronary artery: multimodality imaging assessment and surgical treatment in two cases.

Coronary artery disease·2026
See all related articles

Beta-blockers are now a cornerstone in heart failure treatment, significantly reducing mortality and hospitalizations. Further research is needed to fully optimize their clinical application and understand their mechanisms.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure treatment has evolved from positive inotropic agents to beta-blockers.
  • Beta-blockers, despite negative inotropic effects, are established treatments for heart failure.

Observation:

  • The mechanism of beta-blockers in heart failure likely involves improved cardiac myocyte function and reversal of remodeling.
  • Differentiating characteristics of various beta-blockers do not currently provide a basis for selecting one agent over another.

Findings:

  • Beta-blockers reduce all-cause mortality and hospitalizations by approximately 30-35% in heart failure patients.
  • Responsiveness to beta-blockers is independent of patient demographics, heart failure etiology, or severity.

Implications:

Related Experiment Videos

  • Beta-blockers are recommended as adjunctive therapy for symptomatic heart failure patients.
  • Further research is crucial to fill knowledge gaps for optimal beta-blocker use in heart failure management.
  • The role of beta-blockers is expected to expand with a deeper understanding of heart failure pathophysiology and remodeling.